Published by
The Street
The Street
By PR Newswire PLEASANTON, Calif., Dec. 30, 2021 /PRNewswire/ — Amador Bioscience, a global translational sciences and clinical pharmacology CRO , announced today that it has completed 60MM USD Series B+ financing led by MSA Capital, a global private equity firm . Other participating investors include Series B Co-leads GL Ventures (venture capital arm of Hillhouse Group) and Sequoia Capital, and Series A lead VC Co-win Ventures. Amador Bioscience Completes Series B+ Round Funding. ” Amador’s vision is to be a leading global partner for biotherapeutics R&D success,” said Dr. Bing Wang, Amador …